These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28164801)

  • 1. Beyond intent to treat (ITT): A complier average causal effect (CACE) estimation primer.
    Peugh JL; Strotman D; McGrady M; Rausch J; Kashikar-Zuck S
    J Sch Psychol; 2017 Feb; 60():7-24. PubMed ID: 28164801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regaining power lost by non-compliance via full probability modelling.
    Becque T; White IR
    Stat Med; 2008 Nov; 27(27):5640-63. PubMed ID: 18712776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance effects in a randomised controlled trial of yoga for chronic low back pain: a methodological study.
    Tilbrook HE; Hewitt CE; Aplin JD; Semlyen A; Trewhela A; Watt I; Torgerson DJ
    Physiotherapy; 2014 Sep; 100(3):256-62. PubMed ID: 24530169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Complier Average Causal Effect Parameter for Multiarmed RCTs.
    Schochet PZ
    Eval Rev; 2020 Oct; 44(5-6):410-436. PubMed ID: 33375826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of treatment efficacy with complier average causal effects (CACE) in a randomized stepped wedge trial.
    Gruber JS; Arnold BF; Reygadas F; Hubbard AE; Colford JM
    Am J Epidemiol; 2014 May; 179(9):1134-42. PubMed ID: 24705812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.
    Jo B
    Stat Med; 2002 Nov; 21(21):3161-81. PubMed ID: 12375297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The specific effect of systematic exposure in irritable bowel syndrome: complier average causal effect analysis using growth mixture modeling.
    Hesser H; Hedman E; Lindfors P; Andersson E; Ljótsson B
    Psychol Med; 2017 Nov; 47(15):2653-2662. PubMed ID: 28464975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data.
    Chen H; Geng Z; Zhou XH
    Biometrics; 2009 Sep; 65(3):675-82. PubMed ID: 18759847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of estimands in clinical trials with imperfect compliance.
    Chen H; Heitjan DF
    Int J Biostat; 2024 May; 20(1):57-67. PubMed ID: 37365674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond intention to treat: what is the right question?
    Shrier I; Steele RJ; Verhagen E; Herbert R; Riddell CA; Kaufman JS
    Clin Trials; 2014 Feb; 11(1):28-37. PubMed ID: 24096636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Per-Protocol analyses produced larger treatment effect sizes than intention to treat: a meta-epidemiological study.
    Mostazir M; Taylor G; Henley WE; Watkins ER; Taylor RS
    J Clin Epidemiol; 2021 Oct; 138():12-21. PubMed ID: 34161805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Complier Average Causal Effect in a Meta-Analysis of Randomized Clinical Trials With Binary Outcomes Accounting for Noncompliance: A Generalized Linear Latent and Mixed Model Approach.
    Zhou T; Zhou J; Hodges JS; Lin L; Chen Y; Cole SR; Chu H
    Am J Epidemiol; 2022 Jan; 191(1):220-229. PubMed ID: 34564720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
    Merrill PD; McClure LA
    Trials; 2015 Nov; 16():523. PubMed ID: 26573840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple imputation methods for treatment noncompliance and nonresponse in randomized clinical trials.
    Taylor L; Zhou XH
    Biometrics; 2009 Mar; 65(1):88-95. PubMed ID: 18397338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance mixture modelling with a zero-effect complier class and missing data.
    Sobel ME; Muthén B
    Biometrics; 2012 Dec; 68(4):1037-45. PubMed ID: 22985224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An application of the Complier Average Causal Effect analysis to examine the effects of a family intervention in reducing illicit drug use among high-risk Hispanic adolescents.
    Huang S; Cordova D; Estrada Y; Brincks AM; Asfour LS; Prado G
    Fam Process; 2014 Jun; 53(2):336-47. PubMed ID: 24611528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian hierarchical model estimating CACE in meta-analysis of randomized clinical trials with noncompliance.
    Zhou J; Hodges JS; Suri MFK; Chu H
    Biometrics; 2019 Sep; 75(3):978-987. PubMed ID: 30690716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating treatment effects in randomised controlled trials with non-compliance: a simulation study.
    Ye C; Beyene J; Browne G; Thabane L
    BMJ Open; 2014 Jun; 4(6):e005362. PubMed ID: 24939814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Complier Average Causal Effect Estimation to Determine the Impacts of the Good Behavior Game Preventive Intervention on Teacher Implementers.
    Berg JK; Bradshaw CP; Jo B; Ialongo NS
    Adm Policy Ment Health; 2017 Jul; 44(4):558-571. PubMed ID: 27207372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.